drugset / Trial / NCT06442436
A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015)
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to compare the plasma pharmacokinetics (PK) of nemtabrutinib (MK-1026) following a single oral dose of nemtabrutinib in participants with moderate hepatic impairment to that of healthy matched control participants and to evaluate the safety and tolerability of nemtabrutinib.
Timeline
- Start
- 2024-07-24
- Primary completion
- 2026-09-14
- Completion
- 2026-09-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nemtabrutinib | Other / unclassified | 25 mg | Oral |
Indications
No indication recorded.